Wall Street brokerages expect Kezar Life Sciences, Inc. (NASDAQ:KZR) to announce earnings per share (EPS) of ($0.26) for the current quarter, Zacks reports. Zero analysts have made estimates for Kezar Life Sciences’ earnings, with estimates ranging from ($0.27) to ($0.25). Kezar Life Sciences posted earnings per share of ($0.23) during the same quarter last year, which suggests a negative year over year growth rate of 13%. The company is scheduled to issue its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Kezar Life Sciences will report full year earnings of ($1.02) per share for the current year, with EPS estimates ranging from ($1.05) to ($0.95). For the next year, analysts forecast that the firm will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.51) to ($1.09). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Kezar Life Sciences.
Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Thursday, August 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.01.
A number of large investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its stake in Kezar Life Sciences by 12,201.9% during the 2nd quarter. Morgan Stanley now owns 1,580,546 shares of the company’s stock valued at $8,583,000 after purchasing an additional 1,567,698 shares during the last quarter. Logos Global Management LP increased its holdings in Kezar Life Sciences by 187.5% in the 2nd quarter. Logos Global Management LP now owns 2,300,000 shares of the company’s stock valued at $12,489,000 after buying an additional 1,500,000 shares during the period. Millennium Management LLC increased its holdings in Kezar Life Sciences by 2.7% in the 2nd quarter. Millennium Management LLC now owns 801,361 shares of the company’s stock valued at $4,351,000 after buying an additional 21,079 shares during the period. New York Life Investments Alternatives increased its holdings in Kezar Life Sciences by 36.8% in the 2nd quarter. New York Life Investments Alternatives now owns 78,868 shares of the company’s stock valued at $428,000 after buying an additional 21,198 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Kezar Life Sciences by 17.9% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 90,011 shares of the company’s stock worth $489,000 after purchasing an additional 13,695 shares during the last quarter. Hedge funds and other institutional investors own 57.36% of the company’s stock.
NASDAQ KZR traded up $0.06 during trading on Thursday, reaching $9.35. The company’s stock had a trading volume of 201,288 shares, compared to its average volume of 254,084. The stock has a market capitalization of $450.60 million, a PE ratio of -9.78 and a beta of 0.41. The business has a 50-day moving average price of $6.59 and a 200-day moving average price of $6.06. Kezar Life Sciences has a 1-year low of $4.34 and a 1-year high of $9.79.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
Featured Story: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.